COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorRenJi Hospital

About this trial

In recent years, single-cell high-throughput sequencing technology has developed rapidly and is widely used in research related to the immune system, breaking traditional cognition and gaining a new understanding of immune cell classification. In particular, the emerging single cell RNA sequencing (scRNA-seq) provides new ideas for the study of cell heterogeneity in multicellular organisms. Analyzing the changes in the expression profile of the cell transcriptome at the single-cell level can clearly show the changes in the trajectory of individual cells, reveal new cell types, and discover the potential functions of immune cells. Therefore, this study intends to recruit healthy adults and use multi-omics techniques such as single-cell sequencing to systematically classify the peripheral blood mononuclear cells of healthy adults to provide a basis for further disease-related research.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Healthy adults with Han nationality

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Recently Vaccination

    Biological/Vaccine

Treatment groups

50 Participants
are divided into 4 treatment groups
Group A: Recently unvaccinated group (Female)0 interventions
Group B: Recently unvaccinated group (Male)0 interventions
Group C: Recently vaccinated group (Female)1 intervention
Group D: Recently vaccinated group (Male)1 intervention

Trial outcomes

Primary outcomes

1

Changes in classification of human peripheral blood mononuclear cells

The primary endpoint will be the changes in classification of human peripheral blood mononuclear cells at single cell resolution.

Time frame
up to five years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.